Document Detail


The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors.
MedLine Citation:
PMID:  15596298     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The regulation of secretion of the angiogenic factors CXCL8 and Vascular Endothelial Growth Factors (VEGF) was determined in breast tumor cells and in monocytic cells (as host cells that contribute to breast cancer). CXCL8 secretion, and partly the secretion of VEGF, were up-regulated in monocytic cells, but not in breast tumor cells, by the CC chemokines CCL5 and CCL2. EGF potently up-regulated CXCL8 secretion by breast tumor cells, and its effect was promoted by a consecutive treatment of the cells by estrogen and progesterone. These findings provide evidence for a complex set of pro-malignancy factors that may control the expression of angiogenic mediators at breast tumor sites.
Authors:
Elina Azenshtein; Tsipi Meshel; Sima Shina; Nely Barak; Iafa Keydar; Adit Ben-Baruch
Related Documents :
24391208 - The (1->6)-β-glucan moiety represents a cross-reactive epitope of infection-induced mal...
8007768 - Breast tumor imaging with ultra low field mri.
14751168 - Detection of disseminated tumor cells in peripheral blood of patients with breast cance...
22010578 - E2fbp1 antagonizes the p16(ink4a)-rb tumor suppressor machinery for growth suppression ...
18829538 - Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphan...
18810248 - Orally administered rapamycin, dacarbazine or both for treatment of human melanoma eval...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer letters     Volume:  217     ISSN:  0304-3835     ISO Abbreviation:  Cancer Lett.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2004-12-14     Completed Date:  2005-03-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  73-86     Citation Subset:  IM    
Affiliation:
Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv 69978, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breast Neoplasms / metabolism*
Cell Line, Tumor
Chemokine CCL2 / pharmacology
Chemokine CCL5
Chemokines, CC / pharmacology
Enzyme-Linked Immunosorbent Assay
Epidermal Growth Factor / pharmacology
Estrogens / pharmacology
Humans
Interleukin-8 / metabolism*
Monocytes / metabolism
Neovascularization, Pathologic / metabolism*
Progesterone / pharmacology
Reverse Transcriptase Polymerase Chain Reaction
Vascular Endothelial Growth Factor A / drug effects*,  metabolism
Chemical
Reg. No./Substance:
0/CCL2 protein, human; 0/CCL5 protein, human; 0/Chemokine CCL2; 0/Chemokine CCL5; 0/Chemokines, CC; 0/Estrogens; 0/Interleukin-8; 0/Vascular Endothelial Growth Factor A; 57-83-0/Progesterone; 62229-50-9/Epidermal Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, ...
Next Document:  Inhibition of osteopontin expression and function in oral cancer cell lines by antisense oligonucleo...